Seavi Advent Private Equity (“SEAVI Advent”) completed a US$8m equity investment into Hainan Shuangcheng Pharmaceutical Co Ltd (the “Company”).
The Company is one of the leading Chinese pharmaceutical manufacturers based in Hainan Province of China, engaging in the development, manufacturing and sales of peptide-based pharmaceuticals. The Company’s current product portfolio comprises prescription pharmaceuticals, such as Thymosin α1, Clindamycin Hydrochloride, Levocarnitine, Pantoprazole Sodium, Somatostatin and Sodium Ferulate, which are widely prescribed for the treatment of various ailments. In addition, the Company’s in-house R&D team also works closely with numerous recognised medical institutions to develop new and improved pharmaceutical products.
The Company was incorporated in May 2000 and has set up more than 20 sales offices distributing directly to clinics, hospitals and health care facilities throughout PRC.
Going forward, the Company will continue to build on its core expertise and broaden its product offerings to cater to the rising healthcare demands of the PRC population. The Company will also be expanding its production capacity in tandem with the anticipated increase in demand for its products.
About SEAVI Advent Private Equity
SEAVI Advent Private Equity, the Asian affiliate of Boston based private equity institution Advent International Corporation, is one of the first private equity and venture capital firms to operate in the Asia Pacific region. Since 1984, the firm has invested over US$500 million into many Asian companies, from growth to late stage, as well as buyout and control transactions. SEAVI Advent has been instrumental in delivering value for many of its portfolio companies, which include Yangzijiang Shipbuilding (Holdings) Ltd, Venture Corporation Limited and IDS Group.